Journal of Clinical Oncology
Articles in this Issue
Homologous recombination deficiency signature (HRDsig+) in older women with advanced breast cancer (ABC).
1121 Background: The identification of homologous recombination deficiency (HRD) may expand targeted therapy options in th...
Lymph node ratio in relation to the survival benefit of immediate breast reconstruction in node-positive breast cancer: A population-based cohort study.
e12686 Background: Immediate breast reconstruction (IBR) after mastectomy is increasingly performed, yet its survival impa...
Real-world overall survival outcomes of lutetium (Lu <sup>177</sup> ) vipivotide tetraxetan treatment in prostate cancer.
5033 Background: After FDA approval on March 23, 2022, lutetium (Lu 177 ) vipivoti...
Hetrombopag in patients with chemotherapy-induced thrombocytopenia: A global phase 3, randomized, double-blind study.
TPS12162 Background: Chemotherapy-induced thrombocytopenia (CIT) is a common complication of cancer therapy, frequently re...
Expert validation of an artificial intelligence–enabled trial matching solution using real-world data from patients with cancer.
1501 Background: Under-enrollment in cancer trials remains a major barrier for advancing cancer research in part because f...
Symptoms and life impact of polycythemia vera (PV): Results from a qualitative patient interview study.
e23259 Background: PV is a myeloproliferative neoplasm characterized by excessive red blood cell production. Patients with...
Integration of AI-based risk-stratified therapy to optimize outcomes in localized prostate cancer.
e17131 Background: Androgen deprivation therapy (ADT) is the backbone of systemic treatment for prostate cancer (PCa). How...
Real-world assessment of treatment adherence among vorasidenib-treated patients with IDH-mutant glioma.
e14057 Background: Vorasidenib, a dual inhibitor of mutant IDH1/2 enzymes, was approved in August 2024 as a targeted thera...
The effects of the COVID-19 pandemic on cancer incidence and cancer-specific mortality.
10589 Background: The 2020 COVID-19 pandemic had a significant impact on cancer screening rates and cancer-related outcome...
Serial ctDNA genomic profiling integrated with a networked molecular tumor board in first-line advanced NSCLC: The COPE randomized phase II trial.
8551 Background: Circulating tumor DNA (ctDNA) complements tissue profiling and may provide early response information in...
Real-world patterns of dose reduction and early discontinuation of abemaciclib for early-stage, hormone-receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer in insured United States adults.
e12718 Background: The MonarchE clinical trial of adjuvant abemaciclib 150 mg twice daily in women with early-stage HR+/HE...
Rates of inadequate ovarian suppression in premenopausal breast cancer patients receiving ovarian function suppression.
e12730 Background: Ovarian function suppression (OFS) improves outcomes for premenopausal patients with high-risk estrogen...
Dexrazoxane for anthracycline cardiotoxicity prevention in pediatric and AYA cancers: Systematic review and meta-analysis.
e24201 Background: Anthracyclines remain curative in many pediatric and adolescent/young adult (AYA) cancers but confer do...
Impact of a resident-led quality improvement intervention on colorectal cancer screening completion at a federally qualified health center.
e23306 Background: Colorectal cancer (CRC) remains a leading cause of cancer-related mortality, yet screening rates remain...
Trends in rural-urban disparities in U.S. cervical cancer mortality before and after the HPV vaccine introduction: A CDC analysis, 1999-2023.
5535 Background: Cervical cancer mortality has declined in the United States following the introduction of HPV vaccination...
Assessment of HPV’s influence on survival in head and neck cancer: A pioneering large-scale cohort analysis and insights into HPV’s long-term prognostic impact stratified by smoking status.
e18129 Background: Human papillomavirus (HPV) infection is a prominent risk factor for head and neck cancers (HNC) of the...
Adjuvant immune checkpoint inhibitor therapy after curative-intent resection or ablation for high-risk hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials.
e16289 Background: The risk of recurrence of hepatocellular carcinoma (HCC) remains high after curative-intent resection o...
A prognostic prediction model for neoadjuvant chemotherapy in locally advanced breast cancer integrating deep learning and pathomics.
e12564 Background: Breast cancer is the most prevalent malignant tumor among women worldwide, constituting a significant t...
Temporal trends of mortalities in ovarian carcinoma and hypertension: Comorbidity-related mortality from 1999-2020.
e17590 Background: Ovarian cancer and essential hypertension are both associated with substantial morbidity and mortality...
Does anatomical subsite matter in acral melanoma?: A cohort study of clinical and molecular features.
e21595 Background: Acral melanoma is a rare and biologically distinct melanoma subtype, frequently diagnosed at advanced s...
Cancer incidence and mortality among US young adults younger than 50 years.
e23093 Background: Early-onset cancers are increasingly recognized as a growing public health concern. We aimed to evaluat...
Aumolertinib as first-line therapy for locally advanced or metastatic <i>EGFR</i> -mutant non–small cell lung cancer: A single-arm meta-analysis.
e20715 Background: Patients with EGFR-mutated non-small-cell lung cancer (NSCLC) have a high risk of recurrence and post-s...
Molecular landscape and outcomes of Black and White adults diagnosed with acute myeloid leukemia.
6519 Background: Acute myeloid leukemia (AML) is characterized by poor survival with Black patients (pts) experiencing wor...
TRIPLE-SWITCH (SWOG/CCTG-PR26): A randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive prostate cancer (mCSPC) and suboptimal PSA response (NCT06592924).
TPS5149 Background: Management of patients (pts) with mCSPC remains a challenge due to its incurable nature and heterogene...
SEER-based projections of U.S. meningioma and glioblastoma incidence and survival through 2050.
e14052 Background: Forecasting future central nervous system tumor burden is needed for workforce planning & trial fea...